Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer


Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Mayer EL et al. Prognostic value of genomic analysis after neoadjuvant chemotherapy for breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract P3-10-13.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.